Sotatercept in pulmonary arterial hypertension: revolution, risk and the road ahead
Open Access
- 28 August 2025
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (4) , 2501633
Abstract
Sotatercept, the first approved activin signalling inhibitor (ASI), represents a major advancement in the treatment of pulmonary arterial hypertension (PAH). Met with substantial enthusiasm from patients, caregivers and physicians, sotatercept has the potential to refine, and perhaps even revolutionise, the treatment of PAH. Its novel mechanism of action targets fundamental disease processes, offering the potential of partial disease reversal. Data from a phase 2 study and three phase 3 studies demonstrate robust efficacy. However, unique safety signals have also emerged, both in the clinical trial programme and in post-marketing surveillance. This article summarises the present evidence and outlines steps to optimise the benefit/risk ratio of sotatercept and future ASIs.Keywords
This publication has 33 references indexed in Scilit:
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2022
- Temporal trends in pulmonary arterial hypertension: results from the COMPERA registryEuropean Respiratory Journal, 2021
- Sotatercept for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2021
- An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertensionNature Communications, 2021
- Targeting transforming growth factor-β receptors in pulmonary hypertensionEuropean Respiratory Journal, 2020
- Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosisEBioMedicine, 2020
- ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertensionScience Translational Medicine, 2020
- The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaClinical Cancer Research, 2017
- Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced CancerClinical Cancer Research, 2014
- Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formationBlood, 2013